A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

Healthy Clinical Trial

Official title:

An Expanded Phase1/2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-560, A Live, Attenuated Recombinant Parainfluenza Virus Type 3 (PIV3) Vaccine, Administered Intranasally to Healthy Infants 1 to <12 Mos. of Age

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00508651
• Other study ID #: MI-CP150
• Status: Terminated
• Phase: Phase 1/Phase 2
• First received: July 27, 2007
• Last updated: November 28, 2011
• Start date: October 2007
• Est. completion date: April 2009

Study information

• Verified date: November 2011
• Source: MedImmune LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to describe the safety and tolerability of 3 doses of MEDI-560 at 10^5 TCID50 when administered to children 6 to < 12 months of age who are HPIV3 (human parainfluenza virus type 3) seronegative at baseline and to infants 1 to < 3 months of age regardless of baseline serostatus.

Description:

This is a randomized, double-blind, placebo-controlled, multidose Phase 1/2a multicenter study designed to evaluate the safety, tolerability, viral shedding, immunogenicity, and genotypic and phenotypic stability of MEDI-560 in infants 1 to < 12 months of age. Three doses of MEDI-560 at a dosage level of 10^5 TCID50 were administered 0, 2, and 4 months after enrollment to a 30-participant cohort of 6 to < 12 month-old HPIV3 seronegative children randomized 2:1 to MEDI-560 vs placebo. A second 160-participant cohort of 1 to < 3 month-old infants not screened for baseline serostatus was planned but was not opened to enrollment for reasons other than safety. Participants were followed for safety through 180 days post last dose. Nasal wash specimens were collected at screening and Days 7, 12, and 28 following each dose and during unscheduled illness visits to assess vaccine virus shedding and genotypic and phenotypic stability of any shed vaccine virus. Blood was collected at screening to determine eligibility and prior to Dose 1 for baseline serostatus. Blood for assessment of antibodies to HPIV3 was collected approximately 7 to 12 days after Dose 1 and Dose 3 and 1 month after each dose for antibodies to PIV3.

Other known NCT identifiers

• NCT01150799

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 30
• Est. completion date: April 2009
• Est. primary completion date: April 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 1 Month to 11 Months

Eligibility

Inclusion Criteria:

1. Male or female whose age on the day of randomization falls within one of the two age cohorts:

Cohort 1: 6 to < 12 months (= 6 months of age and not yet reached their 1st year birthday); Cohort 2: 1 to < 3 months (> 28 days of age and not yet reached their 3rd month birthday)

2. Cohort 1 only: Participant is seronegative to HPIV3 at screening as determined by ELISA; or the legal representative is willing to provide access to data documenting that the participant was screened for another MedImmune trial after written informed consent was obtained, and that the participant is seronegative to HPIV3 within 21 days prior to randomization into MI-CP150 as determined by ELISA at MedImmune

3. Participant was the product of a normal full term pregnancy, defined as 36-42 weeks gestation

4. Participant is in general good health

5. Participant's legal representative is available by telephone

6. Written informed consent and Health Insurance Portability and Accountability Act authorization (if applicable) obtained from the participant's legal representative

7. Participant's legal representative is able to understand and comply with the requirements of the protocol as judged by the investigator

8. Participant is available to complete the follow-up period of 180 days after the final dose of investigational product as required by the protocol

9. Participant's legal representative is willing and able to bring the subject to the study site for evaluation of respiratory illness in accordance with the protocol

Exclusion Criteria:

1. Any fever (= 100.4°F [= 38.0°C], regardless of route) or lower respiratory illness within 7 days prior to randomization

2. Moderate or severe nasal congestion that in the investigator's opinion could prevent intranasal delivery of investigational product

3. Cohort 1 only: weight < the fifth percentile for age on the day of randomization

4. Cohort 2 only: history of low birth-weight (ie, < 2,500 grams at birth) or weight < fifth percentile for age on the day of randomization

5. Any drug therapy (chronic or other) within 7 days prior to randomization or expected receipt through the protocol-specified blood collection 28 days after each investigational product dosing, except that infrequent use of over-the-counter medications such as pain relievers are permitted according to the judgment of the investigator

6. Any current or expected receipt of immunosuppressive agents including steroids (= 2 mg/kg per day of prednisone or its equivalent, or = 20 mg/day if the participant weighs >10 kg, given daily or on alternate days for = 14 days); children in this category should not receive investigational product until immunosuppressive agents including corticosteroid therapy have been discontinued for = 30 days; the use of topical steroids is permitted according to the judgment of the investigator

7. History of receipt of blood transfusion or expected receipt through 30 days after final investigational product dosing

8. History of receipt of immunoglobulin products or expected receipt through 30 days after final investigational product dosing

9. Receipt of any investigational drug within 60 days prior to randomization or expected receipt through 30 days after final investigational product dosing

10. Receipt of any live virus vaccine (excluding rotavirus vaccine) within 28 days prior to randomization or expected receipt within a 28-day window around any dose

11. Receipt of any inactivated (eg, non-live) vaccine or rotavirus vaccine within 14 days prior to randomization or expected receipt within a 14-day window around any dose

12. Known or suspected immunodeficiency, including human immunodeficiency virus

13. Living in the same home or enrolled in the same classroom at day care with infants < 24 months of age within 28 days after each dose (only one child per household may be enrolled into the study)

14. Contact with pregnant caregiver within 28 days after each dose

15. Household contact with an immunocompromised person within 28 days after each dose; the participant should also avoid close contact with immunocompromised individuals for at least 28 days after each investigational product dose

16. Household contact within 28 days after each dose with a healthcare worker who has direct patient care responsibilities or household contact within 28 days after each dose with someone who is a day care provider or preschool teacher for children < 24 months of age

17. History of allergic reaction to any component of the investigational product

18. Previous medical history or evidence of an intercurrent or chronic illness that, in the opinion of the investigator, may compromise the safety of the participant

19. Known or suspected active or chronic hepatitis infection

20. History of medical diagnosis of asthma, reactive airway disease, wheezing requiring medication, bronchoconstriction or treatment with a ß2 agonist (eg, albuterol), cystic fibrosis, chronic lung disease of prematurity (eg, bronchopulmonary dysplasia), chronic pulmonary disease, medically confirmed apnea, hospitalization for respiratory illness or mechanical ventilation

21. A family member or a household contact who is an employee of the research center or otherwise involved with the conduct of the study

22. Any condition that, in the opinion of the investigator, might interfere with investigational product evaluation

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Healthy

Intervention

Biological:
• MEDI-560
MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
• Placebo
Placebo was a frozen preparation filled into Becton Dickinson^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.

Locations

Country	Name	City	State
United States	Children's Investigational Research Program	Bentonville	Arkansas
United States	St. Luke's Hospital	Bethlehem	Pennsylvania
United States	Tufts-New England Medical Center	Boston	Massachusetts
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	University Hospitals Case Medical Center	Cleveland	Ohio
United States	Duke Health Center- Pickett Road	Durham	North Carolina
United States	Kapiolani Medical Center for Women and Children	Honolulu	Hawaii
United States	University Physicians Internal Medicine	Huntington	West Virginia
United States	Holston Medical Group	Kingsport	Tennessee
United States	Children's Lung Specialists Ltd.	Las Vegas	Nevada
United States	Michael W. Simon, M.D.	Lexington	Kentucky
United States	Arkansas Pediatric Clinic	Little Rock	Arkansas
United States	Madera Family Medical Group	Madera	California
United States	Miami Children's Hospital	Miami	Florida
United States	Homestead Clinical Research	Naranja	Florida
United States	Tulane University	New Orleans	Louisiana
United States	Meridian Clinical Research LLC	Omaha	Nebraska
United States	Belleview Pediactric Assoc.	Pittsburgh	Pennsylvania
United States	Allergy Medical Group of the North Area	Roseville	California
United States	Dixie Pediatrics	St. George	Utah
United States	SUNY Upstate Medical University	Syracuse	New York
United States	University of South Florida College of Medicine Department of Pediatrics	Tampa	Florida
United States	Oklahoma State University Center for Health Sciences	Tulsa	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
MedImmune LLC

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bernstein DI, Falloon J, Yi T. A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants. Vaccine. 2011 Sep 16;29(40):7042-8. doi: 10 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Solicited Adverse Events (SEs) After Dose 1		Days 0-28 after Dose 1 (Dose 1 was on Day 0)	Yes
Primary	Number of Participants With SEs After Dose 2		Days 0-28 after Dose 2 (Dose 2 was on Day 48-64)	Yes
Primary	Number of Participants With SEs After Dose 3		Days 0-28 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	Yes
Primary	Number of Participants With Adverse Events (AEs) After Dose 1	Unsolicited AEs reported by 1 or more participants in either treatment group through 28 days post Dose 1.	Days 0-28 after Dose 1 (Dose 1 was on Day 0)	Yes
Primary	Number of Participants With AEs After Dose 2	Unsolicited AEs reported by 1 or more participants in either treatment group through 28 days post Dose 2.	Days 0-28 after Dose 2 (Dose 2 was on Day 48-64)	Yes
Primary	Number of Participants With AEs After Dose 3	Unsolicited AEs reported by 1 or more participants in either treatment group through 28 days post Dose 3.	Days 0-28 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	Yes
Primary	Number of Participants With Medically Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 1		Days 0-28 after Dose 1 (Dose 1 was on Day 0)	Yes
Primary	Number of Participants With MA-LRIs After Dose 2		Days 0-28 after Dose 2 (Dose 2 was on Day 48-64)	Yes
Primary	Number of Participants With MA-LRIs After Dose 3		Days 0-28 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	Yes
Primary	Number of Participants With Serious Adverse Events (SAEs) After Dose 1		Days 0-28 after Dose 1 (Dose 1 was on Day 0)	Yes
Primary	Number of Participants With SAEs After Dose 2	One participant had event of pneumonia after Dose 2.	Days 0-28 after Dose 2 (Dose 2 was on Day 48-64)	Yes
Primary	Number of Participants With SAEs After Dose 3		Days 0-28 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	Yes
Primary	Number of Participants With Significant New Medical Conditions (SNMCs)	A SNMC is a newly diagnosed medical condition that is of a chronic, ongoing nature and is assessed by the investigator as medically significant.	Day 0 through 180 days after final dose	Yes
Secondary	Number of Participants Shedding Vaccine-like Virus at Any Time During Study Participation	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 7, 12, and 28 after each dose and during visits for pre-specified illness symptoms occurring Day 0 through 180 days post final dose.	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 7 Days After Dose 1	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 7-10 after Dose 1 (Dose 1 was on Day 0)	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 12 Days After Dose 1	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 12-18 after Dose 1 (Dose 1 was on Day 0)	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 28 Days After Dose 1	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 28-34 after Dose 1 (Dose 1 was on Day 0)	No
Secondary	Number of Participants With Shedding of Vaccine-like Virus on Any Day During Days 0-28 After Dose 1		Days 0-34 after Dose 1 (Dose 1 was on Day 0)	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 7 Days After Dose 2	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 7-10 after Dose 2 (Dose 2 was on Day 48-64)	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 12 Days After Dose 2	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 12-18 after Dose 2 (Dose 2 was on Day 48-64)	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 28 Days After Dose 2	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 28-34 after Dose 2 (Dose 2 was on Day 48-64)	No
Secondary	Number of Participants With Shedding of Vaccine-like Virus on Any Day During Days 0-28 After Dose 2	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 0-34 after Dose 2 (Dose 2 was on Day 48-64)	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 7 Days After Dose 3	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 7-10 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 12 Days After Dose 3	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 12-18 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	No
Secondary	Number of Participants Shedding Vaccine-like Virus at 28 Days After Dose 3	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	No
Secondary	Number of Participants With Shedding of Vaccine-like Virus on Any Day During Days 0-28 After Dose 3.	Number of participants with nasal wash specimens that were culture positive for HPIV3 in which vaccine-like virus was identified.	Days 0-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	No
Secondary	Number of Participants With Hemagglutination Inhibition (HAI) Seroconversion/Seroresponse to HPIV3 28 Days After Dose 1	Hemagglutination inhibition seroconversion/seroresponse is equal to or greater than a 4-fold rise in HAI antibody titer from baseline. Hemagglutination inhibition antibody results obtained on or after detection of wild-type HPIV3 in culture were not considered valid.	Days 28-34 after Dose 1 (Dose 1 was on Day 0)	No
Secondary	Number of Participants With HAI Seroconversion/Seroresponse to HPIV3 28 Days After Dose 2	Hemagglutination inhibition seroconversion/seroresponse is equal to or greater than a 4-fold rise in HAI antibody titer from baseline. Hemagglutination inhibition antibody results obtained on or after detection of wild-type HPIV3 in culture were not considered valid.	Days 28-34 after Dose 2 (Dose 2 was on Day 48-64)	No
Secondary	Number of Participants With HAI Seroconversion/Seroresponse to HPIV3 28 Days After Dose 3	Hemagglutination inhibition seroconversion/seroresponse is equal to or greater than a 4-fold rise in HAI antibody titer from baseline. Hemagglutination inhibition antibody results obtained on or after detection of wild-type HPIV3 in culture were not considered valid.	Days 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	No
Secondary	Number of Nasal Wash Samples Containing Vaccine-like Virus in the Absence of Admixture With Wild-type HPIV3 in Which the Vaccine-like Virus Was Genotypically Stable	A nasal wash specimen was collected at screening and on Days 7 (7-10), 12 (12-18), and 28 (28-34) post each dose and during visits for pre-specified illness symptoms occurring Day 0 through 180 days post final dose to assess vaccine virus replication. Genotypic stability of recovered vaccine-type virus at the 15 mutations of phenotypic importance was assessed.	Day 0 after Dose 1 to 180 days after the final dose	No
Secondary	Number of Nasal Wash Samples Containing Vaccine-like Virus in the Absence of Admixture With Wild-type HPIV3 in Which the Vaccine-like Virus Was Phenotypically Stable	A nasal wash specimen was collected at screening and on Days 7 (7-10), 12 (12-18), and 28 (28-34) post each dose and during visits for pre-specified illness symptoms occurring Day 0 through 180 days post final dose to assess vaccine virus replication. Determination of the temperature sensitivity of recovered vaccine-type virus.	Day 0 after Dose 1 to 180 days after the final dose	No
Secondary	Geometric Mean Titers (GMTs) of Serum HAI Antibodies to HPIV3 at Baseline	Pre-dose GMT of HAI antibody to HPIV3	Baseline (Day 0 prior to Dose 1)	No
Secondary	Geometric Mean Titers of Serum Antibodies to HPIV3 Day 28 Post Dose 1	Post-Dose 1 GMT of HAI antibody to HPIV3	Day 28-34 after Dose 1 (Dose 1 was on Day 0)	No
Secondary	Geometric Mean Titers of Serum Antibodies to HPIV3 Day 28 Post Dose 2	Post-Dose 2 GMT of HAI antibody to HPIV3	Day 28-34 after Dose 2 (Dose 2 was on Day 48-64)	No
Secondary	Geometric Mean Titers of Serum Antibodies to HPIV3 Day 28 Post Dose 3	Post-Dose 3 GMT of HAI antibody to HPIV3	Day 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.